Introduction 49
Measuring genome-wide changes in transcript abundance in circulating peripheral whole blood cells is a 50 useful way to study disease pathobiology [1] . By providing a relatively comprehensive survey of the 51 status of the immune system, peripheral whole blood transcript abundances may help elucidate 52 molecular mechanisms [2] . The sensitivity and interpretability of analyses carried out in this tissue, 53 however, are significantly affected by its dynamic heterogeneity [3] . It is therefore desirable to quantify 54 this heterogeneity, either to account for it or to model interactions that may be present between the 55 abundance of certain transcripts, some cell types, and some phenotypic indication. 56 Accurate enumeration of the many component cell types that make up peripheral whole blood can be 57 costly, however, and may further complicate the sample collection process, beyond a simple complete 58 blood count and leukocyte differentials (CBC/Diffs). Further, the majority of publicly available peripheral 59 whole blood-derived gene expression profiles on the Gene Expression Omnibus [4] do not include any 60 composition information. Accurate quantification of the cellular composition of blood samples from 61 gene expression data without performing additional experiments is useful, allowing for re-analysis of 62 existing public data, for example. 63
Many approaches have been developed to infer the cellular composition of a sample from high-64 dimensional transcriptomic [3, 5-10] and, more recently, DNA methylation data [11, 12] . Briefly, if X, W, 65 and H are matrices with entries X ij (observed expression for sample i, gene j), w ik (composition for 66 sample i, cell type k), and h kj (cell type-specific contribution to the observed expression for cell type k, 67 gene j), then the problem can be stated: having observed X, we wish to estimate W, based on the 68 assumed relationship between expression and composition: 69
where represents the expression information for sample i, gene j that is not predictable by the cell 71 composition. 72 We further assume that, for each component cell type k, there exists a subset of features X k ij' in X whose 73 observed expression in sample i is proportional to the relative abundance of cell type k in sample i. 74
More formally: 75
These composition-discriminating features are termed marker genes. For such genes, the elements of 77 the H can be derived from omics profiles of isolated cell types obtained from reference datasets, and W 78 estimated by regression [5, [7] [8] [9] [10] [11] [12] [13] . Importantly, mapping such marker genes across technology platforms 79 is not always tractable. Not all genes can be readily mapped across gene expression platforms and the 80 values derived from reference datasets may be specific to the platform on which the gene expression 81 was measured. This limits application of these techniques to platforms on which suitable reference 82 datasets exist. Unfortunately, generating such datasets is costly, and they are correspondingly rare. 83
More recently, so-called reference-free approaches have been proposed to address this issue [6, 14] . 84
When applied to transcriptomic data, these approaches still require the identification of suitable marker 85 genes for the cell types to be quantified. This selection is of paramount importance to achieve optimal 86 performance. The general strategy for marker selection is to identify genes whose expression in one cell 87 type exceeds that of all other cell types being considered [6], a process that itself relies on reference 88 datasets. In fact, all approaches discussed thus far rely on one of a handful of publicly available 89 reference datasets to derive a basis matrix or identify suitable marker genes [12, 15, 16] . No suitable 90 reference dataset exists on the newer Affymetrix Gene ST platform. 91
Here we propose a new approach that leverages a multi-task learning algorithm to construct a statistical 92 model able to predict the composition of peripheral whole blood from Affymetrix Gene ST expression 93 profiles. We further show that the coefficients of this model can be used to identify suitable marker 94 genes directly, without the need for a reference dataset. Our strategy is readily applicable to other 95 tissues and/or platforms, which would allow for the development of tools to accurately segment and 96 quantify a variety of admixed tissues from their gene expression profiles, to account for cellular 97 heterogeneity across indications or model interactions between gene expression, some cell types and 98
the indication under study. The described model is freely-available and open source, outperforms other 99 current methods when applied to Gene ST data, and could significantly improve our ability to study 100 disease pathobiology in blood by allowing a more complete study of the various components of the 101 immune compartment of blood from whole blood gene expression. 102 
Patients, material, and methods

Sample processing
129 For all subjects, blood was collected in PAXgene (PreAnalytix, Switzerland) and EDTA tubes. The EDTA 130 blood was spun down (200 x g for 10 minutes at room temperature) and the buffy coat aliquoted out. 131
Both PAXgene blood and buffy coat samples were stored at -80 o C. 132
Transcript abundance 133
Total RNA was extracted from PAXgene blood on the QIAcube (Qiagen, Germany), using the PAXgene 134 Blood miRNA kit from PreAnalytix, according to manufacturer's instructions. Human Gene 1.1 ST array 135 plates (Affymetrix, United States) were used to measure mRNA abundance. This work was carried out at 136
The Scripps Research Institute DNA Array Core Facility (TSRI; La Jolla, CA). The resulting CEL files were 137 processed using the 'oligo' R package [17] . 138
Dna methylation 139
For the RTP cohort samples only, DNA was extracted from buffy coat using Qiagen's QIAamp DNA Blood 140 Mini kits. DNA was bisulphate-converted using the Zymo Research EZ DNA methylation conversion kit, 141
and Infinium HumanMethylation450 BeadChips (Illumina, United States) were used to measure 142 methylation status at >485,000 sites across the genome. This work was carried out at The Centre for 143 Applied Genomics (TCAG; Toronto, Canada). The resulting IDAT files were processed using the 'minfi' R 144 package [18] . 145
Statistical analysis
146 Following preprocessing with their respective packages ('oligo' or 'minfi'), the normalized data were 147 batch corrected using the 'ComBat' algorithm [19] , as implemented in the 'sva' R package [20] . 148
Model training 149
Next, we inferred the cellular composition of the RTP cohort blood samples from their DNA methylation 150 profiles using the 'estimateCellCounts' function provided by 'minfi'. This function uses publicly available 151 DNA methylation profiles obtained from isolated leukocyte sub-types to infer the relative abundance of 152 granulocytes, monocytes, B, CD4+ T, CD8+ T and NK cells (details in Table 1 ) with very high accuracy [12, 153 18]. We compared these composition estimates to those obtained from a hematology analyzer 154 (CBC/Diffs) to assess accuracy. 155
We then fit a multi-response Gaussian model using elastic net regression via the 'glmnet' R package [21] 156 on the genome-wide transcript abundance data, using the DNA methylation-derived cell proportions as 157 response variables. The multi-response Gaussian model family is useful when there are a number of 158 possibly correlated responses -a so called "multi-task learning" problem -as is the case for these cell 159
proportions. Probesets with minimum log 2 expression < 5.5 across all samples (22,251) were excluded 160 using the 'exclude' parameter. We set the elastic net mixing parameter 'alpha' at 0.1 to encourage the 161 selection of a smaller subset of genes and chose the regularization parameter 'lambda' using the 162 'cv.glmnet' function set to minimize mean squared error (MSE). 163
Estimating out-of-sample performance 164
Out-of-sample performance of our model was evaluated using 20 x 10-fold cross-validation (not to be 165 confused with the cross-validation performed by 'cv.glmnet' in order to choose an effective regularization parameter 'lambda'). We then validated the accuracy and calibration of our model by 167 comparing its predicted cell proportions to the available CBC/Diffs data in the CHFP cohort. 168
Unfortunately, a more complete enumeration of the lymphocyte compartment (e.g., by flow cytometry) 169 was not available in any of our cohorts, so we could not independently validate performance in the 170 various lymphocyte sub-types. Instead, the sum of the predicted B, CD4+ T, CD8+ T and NK cell 171
proportions was compared to total lymphocyte proportions from the CBC/Diffs. 172
Performance compared to other current approaches 173
Finally, we compared the performance of our model to two alternative approaches for determining the 174 composition of blood samples from their gene expression profiles, described by Abbas et al. 
Model features as marker genes for use with reference-free approaches 182
Next, we evaluated whether our approach could be used to identify more suitable marker gene sets 183 compared to a reference dataset approach. The reference-free approach described by Chikina et al. 184 does not require a basis matrix, relying instead on a set of putative marker genes. These are used to 185 guide the decomposition of the dataset's covariance structure into separate variance components, using 186 singular value decomposition (SVD). Marker genes for each cell type are summarized in this manner, a 187 technique known as eigengene summarization [22] . Given a good set of marker genes, these 188 summarized values, termed surrogate proportion variables, should track with mixture proportions. We 189 used the reference-free approach described by Chikina To characterize the potential performance of this model on new data, we carried out a 20 x 10-fold 209 cross-validation. Estimated out-of-sample performance varied across cell types (Figure 3) . We report the 210 mean rmse (scaled to the expected cell abundance) and Spearman's ρ across all 200 generated models. 211
Scaled rmse was lowest for granulocytes (0.08) and monocytes (0.24), higher in B, NK and CD4+ T cells Finally, we applied the model to predict the composition of the RTP cohort blood samples from their 232 gene expression. This is a contrived example, as this information was already available to us, but it 233 serves to illustrate a possible application of the approach. As expected, large differences exist in the 234 proportions of the various cell types between patients given prednisone or not. Patients on prednisone 235 had proportionally lower amounts of monocytes (p = 2.9 x 10 -4 ), B (p = 6.6 x 10 -5 ), CD4+ T (p = 6.6 x 10 -7 ), 236 CD8+ T (p = 5.0 x 10 -10 ) and NK cells (p = 9.3 x 10 -10 ), and proportionally higher amounts of granulocytes 237 (p = 2.3 x 10 -8 ). 238
Discussion
239
We introduce a statistical model for predicting the composition of blood samples from Affymetrix Gene 240 ST gene expression profiles. We demonstrate that this model has suitable performance across all 241 included cell types in cross-validation, and validate its performance in an independent cohort. The 242 training and validation cohorts represent 2 major clinical indications, COPD and CHF, and include 243 patients with various comorbidities, on various drugs, some with strong effects on blood gene 244 expression (e.g., prednisone), suggesting that our model may generalize well and be broadly applicable. 245
All training and validation samples were from older individuals, however, and it may be that this model 246 will not generalize well to pediatric populations. A loss of performance in pediatric population has been 247 noted when using a similar approach with DNA methylation data [23] . 248
We also show that platform-specific marker gene sets can be derived without the need for reference 249 datasets of isolated gene expression profiles for the cell types we wish to enumerate. Using marker 250 genes selected from the coefficients of our model in combination with the reference-free approach 251 proposed by Chikina et al. resulted in better performance compared to using marker genes derived from 252 isolated leukocyte gene expression profiles obtained on another microarray platform. Interestingly, the 253 reference-free approach performed only slightly worse than our model, although with loss of scale. This 254 suggests that the non-zero coefficient weights of the model (which we used to select marker genes for 255 the various included cell types) can be estimated entirely in the data, and that these marker genes may 256 be context-independent surrogates of cell proportions. 257
More generally, the strategy we adopted to derive our model (and identify suitable marker genes) could 258 be readily applied to other platforms, or tissues of interest. The only requirements are accurate 259 quantification of the cell types of interest across a large cohort with matched omics profiling. For many 260 popular platforms (e.g., RNA-seq), this schema may be more cost effective than sorting and profiling a 261 number of replicates for all cells of interest, particularly when we consider how costs would scale with 262 additional cell types to be quantified. Moreover, for low abundance cell types, obtaining a sufficient 263 quantity to profile may not be feasible, depending on the efficiency of available separation techniques, 264 amount of admixed tissue that can be collected in practice. 265
The lack of independent validation within the lymphocyte sub-types is a limitation, though cross-266 validation performance was good across all cell types. We believe it is unlikely that poor performance in 267 some or all lymphocyte sub-types would result in good performance when summed and compared to 268 CBC/Diffs. Model fit exhibits some degree of shrinkage (flattening of the plot of predicted vs. observed 269 away from the 45 degree line). This is expected, however, and related to the phenomenon of regression 270 to the mean. Performance in cross-validation was notably worse for CD8+ T cells. This could be because 271 of the preponderance of zero values for this particular cell type. We also note that performance in 272 monocytes drops significantly in the validation cohort. It is unclear why this is, but one possibility is the 273 difference in the distribution of values in the validation cohort (mean monocyte proportion in training: 274 0.073 vs. 0.090 in the validation; p = 1.39 x 10 -7 ). We have observed poor performance of various 275 deconvolution approaches in quantifying monocytes in the past [13, 24] . It might be that circulating 276 monocyte diversity is poorly reflected in our current framework and we may be selecting poor marker 277 genes for this cell type as a result. A similar rationale could be applied to explain the poor CD8+ T cell 278 performance results in cross-validation. Certainly, it offers the opportunity for further exploration of the 279 true complexity of these cell types in peripheral blood. 280
In summary, our freely-available, open source statistical model is capable of accurately inferring the 281 composition of peripheral whole blood samples from Affymetrix Gene ST expression profiles. The 282 strategy we adopted to derive this model is readily applicable to other tissues and/or platforms, which 283 would allow for the development of tools to accurately segment and quantify a variety of admixed 284 tissues from their gene expression profiles, to account for cellular heterogeneity across indications or 285 model interactions between gene expression, some cell types and the indication under study. The 286 described model outperforms other current methods when applied to Gene ST data and significantly 287 improves our ability to study disease pathobiology in blood. We provide the opportunity to enrich the 288 >10,000 Affymetrix Gene ST blood gene expression profiles currently available on GEO, by allowing a 289 more complete study of the various components of the immune compartment of blood from whole 290 blood gene expression. 291
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